Business ❯ Pharmaceuticals

Mergers and Acquisitions

Corporate Strategy Pfizer Legal Disputes Investment Bidding Wars Takeover Bids Drug Development Antitrust Issues Sanofi Biontech Weight-loss Drugs Weight Loss Corporate Transactions BioNTech Valuation Obesity Treatments Acquisitions Investment Funds Market Competition Market Strategy Biotechnology Acquisition Transactions Competitive Strategy Company Strategy Bristol Myers Squibb Corporate Competition Corporate News Acquisition Strategies Healthcare Pharma Industry Novo Nordisk vs Pfizer Novo Nordisk Antitrust Law Company Acquisition Tender Offer Federal Trade Commission Foreign Investment Novartis Company Acquisitions AstraZeneca BioMarin

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

The all-cash deal gives the Italian group a U.S. foothold to scale a Brain Health–focused rare-disease platform.

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Pfizer Sues Metsera and Novo Nordisk to Block Termination of $4.9 Billion Deal

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Pfizer Strikes U.S. Drug-Pricing Pact, Wins Exemption From 100% Import Tariff

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy